Ambry

The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.

My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.

The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.